A Randomized Phase II Trial of Atezolizumab with or without Bevacizumab in Cisplatin-ineligible Patients with Advanced/Unresectable Urothelial Cancer | NYU Langone Health

Go Back to All Clinical Trials

A Randomized Phase II Trial of Atezolizumab with or without Bevacizumab in Cisplatin-ineligible Patients with Advanced/Unresectable Urothelial Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Urothelial Cancer
Age: Between 18 years - 90 years
Gender: Male or Female

Other Inclusion Criteria:

1. Histologic or cytological evidence of urothelial (transitional cell) carcinoma of the renal pelvis, ureter, bladder or urethra. 2. Locally advanced/unresectable disease as determined by site attending urologic oncologist or metastatic disease. 3. No prior chemotherapy for inoperable locally advanced or metastatic urothelial carcinoma

You may not be eligible for this study if the following are true:

1. Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment 2. Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment 3. Active or untreated CNS metastases as determined by CT or MRI evaluation during screening and prior radiographic assessments.